Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG‑350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded… read more →
PsiOxus Therapeutics, Ltd. (PsiOxus), a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. (Nasdaq: BLUE) presented preclinical… read more →
Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour* and Margaret R. Duffy
Journal for ImmunoTherapy of Cancer (2019) 7:320
Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, Duffy MR, Seymour LW. EMBO Mol Med 9:1067-1087 (2017)
JD Freedman, MR Duffy, J Lei-Rossmann, A Muntzer, EM Scott, J Hagel, L Campo, RJ Bryant, C Verrill, A Lambert, P Miller, BR Champion, LW Seymour and KD Fisher. Cancer Res 2018, 1–14, AACR.
Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, Brown ACN. PLoS One 2017;12(5):e0177810.
A multicenter, open-label, first in human study of a vector expressing and agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors.
NG-641: A T-SIGn vector targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas.
